AI MARKET SCANNING

Kalaris Therapeutics Inc

📅 Next Catalyst: Nov 18, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP -0.60%
MAX GAP RECORD -2.71%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $KLRS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 18, 2026 Earnings Release 2026-11-18 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 11, 2026 Earnings Release 2026-08-11 (AFTER CLOSE)
+2.52%
May 12, 2026 Earnings Release 2026-05-12 (AFTER CLOSE)
-2.71%
Mar 17, 2026 Earnings Release 2026-03-17 (UNDETERMINED)
+0.00%
Nov 12, 2025 Earnings Release 2025-11-12 (UNDETERMINED)
+0.00%
Aug 13, 2025 Earnings Release 2025-08-13 (BEFORE OPEN)
-1.61%
May 14, 2025 Earnings Release 2025-05-14 (UNDETERMINED)
+0.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.3%
Bullish Gaps (1)
Bearish Gaps (2)
Neutral / Flat (0)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $KLRS

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗